Display options
Cite
Boiko AS, Mednova IA, Kornetova EG, et al. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. Neuropsychiatr Dis Treat. 2020;16:1051-1058doi: 10.2147/NDT.S247161.
Boiko, A. S., Mednova, I. A., Kornetova, E. G., Bokhan, N. A., Semke, A. V., Loonen, A. J. M., & Ivanova, S. A. (2020). Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. Neuropsychiatric disease and treatment, 161051-1058. https://doi.org/10.2147/NDT.S247161
Boiko, Anastasiia S, et al. "Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia." Neuropsychiatric disease and treatment vol. 16 (2020): 1051-1058. doi: https://doi.org/10.2147/NDT.S247161
Boiko AS, Mednova IA, Kornetova EG, Bokhan NA, Semke AV, Loonen AJM, Ivanova SA. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. Neuropsychiatr Dis Treat. 2020 Apr 22;16:1051-1058. doi: 10.2147/NDT.S247161. eCollection 2020. PMID: 32368067; PMCID: PMC7184116.
Copy Download .nbib Format: NLM
Share it on

Neuropsychiatr Dis Treat. 2020 Apr 22;16:1051-1058. doi: 10.2147/NDT.S247161. eCollection 2020.

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia.

Neuropsychiatric disease and treatment

Anastasiia S Boiko, Irina A Mednova, Elena G Kornetova, Nikolay A Bokhan, Arkadiy V Semke, Anton J M Loonen, Svetlana A Ivanova

Affiliations

  1. Mental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation.
  2. Hospital, Siberian State Medical University, Tomsk, Russian Federation.
  3. Psychiatry, Addictology and Psychotherapy, Siberian State Medical University, Russian Federation.
  4. PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.

PMID: 32368067 PMCID: PMC7184116 DOI: 10.2147/NDT.S247161

Abstract

BACKGROUND: Both dehydroepiandrosterone (DHEAS) and cortisol are secreted by the adrenal glands and may modulate metabolic syndrome (MetS), which often affects the health of patients with schizophrenia. The relationship between the serum levels of these hormones and MetS has not been established.

PURPOSE: In this pilot study, we investigated the serum levels in schizophrenia patients with and without MetS and compared them with those in healthy volunteers.

PATIENTS AND METHODS: After obtaining informed consent, 110 patients with acute paranoid schizophrenia were recruited directly after admission to the Mental Health Research Institute. The control group consisted of 51 persons reported on questioning to be mentally and somatically healthy. Blood samples to prepare serum were drawn after an 8-h overnight fast during one of the first days of admission. Serum cortisol and DHEAS concentrations were quantified by enzyme-linked immunosorbent assay.

RESULTS: A total of 42 patients had MetS and 68 patients were without MetS. The cortisol blood level was significantly (p = 0.012) higher in schizophrenia patients without MetS in comparison to healthy controls, while patients with schizophrenia and a MetS have significantly (p = 0.014) lower DHEAS levels than healthy volunteers. These differences could, however, exclusively be attributed to female participants. Analysis of covariance adjusted for gender and age demonstrated a significant relationship between age and DHEAS levels (F = 9.512, р = 0.003).

CONCLUSION: Lower DHEAS serum levels in relationship to MetS become evident in women, but not in men, and have age differences as a confounding factor.

© 2020 Boiko et al.

Keywords: acute relapse; cortisol; dehydroepiandrosterone; female; metabolic syndrome; schizophrenia

Conflict of interest statement

Dr Anastasiia S Boiko reports grants from the Russian Science Foundation, during the conduct of the study. Dr Irina A Mednova reports grants from the Russian Science Foundation, during the conduct of

References

  1. Biofactors. 2015 May 6;41(3):153-9 - PubMed
  2. Psychoneuroendocrinology. 2018 Sep;95:50-62 - PubMed
  3. Schizophr Bull. 2013 Mar;39(2):295-305 - PubMed
  4. J Mol Neurosci. 2004;23(3):205-12 - PubMed
  5. J Clin Endocrinol Metab. 1997 Aug;82(8):2578-85 - PubMed
  6. Diabetes. 2009 Sep;58(9):2027-31 - PubMed
  7. Drug Saf. 2017 Sep;40(9):771-781 - PubMed
  8. Psychoneuroendocrinology. 2017 Oct;84:87-93 - PubMed
  9. Curr Diabetes Rev. 2017;13(3):528-532 - PubMed
  10. Clin Neuropharmacol. 2012 May-Jun;35(3):141-7 - PubMed
  11. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S59-63 - PubMed
  12. Ann Med. 2005;37(3):173-8 - PubMed
  13. Neth J Med. 2014 Feb;72(2):62-72 - PubMed
  14. Asian J Psychiatr. 2015 Dec;18:2-14 - PubMed
  15. Eur J Endocrinol. 2010 May;162(5):919-23 - PubMed
  16. Psychiatr Danub. 2014 Jun;26(2):187-9 - PubMed
  17. Vitam Horm. 2018;108:355-365 - PubMed
  18. Neuro Endocrinol Lett. 2011;32(2):141-7 - PubMed
  19. J Psychiatr Res. 2013 Nov;47(11):1549-56 - PubMed
  20. PLoS One. 2018 Apr 12;13(4):e0195687 - PubMed
  21. Am J Physiol Endocrinol Metab. 2013 Nov 1;305(9):E1134-44 - PubMed
  22. Endocrinol Metab Clin North Am. 2014 Mar;43(1):1-23 - PubMed
  23. Lancet Psychiatry. 2017 Apr;4(4):295-301 - PubMed
  24. J Steroid Biochem Mol Biol. 2017 Apr;168:9-18 - PubMed
  25. Diabetes Metab Syndr. 2018 Apr - Jun;12(2):135-140 - PubMed
  26. Front Neuroendocrinol. 2009 Jan;30(1):65-91 - PubMed
  27. Horm Mol Biol Clin Investig. 2013 Aug;14(2):65-74 - PubMed
  28. Psychoneuroendocrinology. 2019 Jun;104:269-275 - PubMed
  29. J Clin Invest. 2017 Apr 3;127(4):1136-1145 - PubMed
  30. Curr Cardiol Rep. 2014 Apr;16(4):467 - PubMed
  31. Psychoneuroendocrinology. 2018 Mar;89:92-102 - PubMed
  32. Endocr Metab Immune Disord Drug Targets. 2018;18(4):348-354 - PubMed
  33. Psychoneuroendocrinology. 2014 Jan;39:1-10 - PubMed
  34. J Allergy Clin Immunol. 2013 Nov;132(5):1033-44 - PubMed
  35. Curr Top Behav Neurosci. 2020;44:49-66 - PubMed
  36. Eur J Clin Invest. 2009 Feb;39(2):81-93 - PubMed
  37. Schizophr Bull. 2013 Mar;39(2):306-18 - PubMed
  38. Clin Endocrinol (Oxf). 2014 Nov;81(5):775-83 - PubMed
  39. J Psychopharmacol. 2012 May;26(5 Suppl):33-41 - PubMed
  40. J Endocrinol. 2005 Nov;187(2):169-96 - PubMed
  41. Psychoneuroendocrinology. 2014 Nov;49:187-206 - PubMed
  42. World Psychiatry. 2015 Oct;14(3):339-47 - PubMed
  43. Heliyon. 2019 Jul 03;5(7):e02033 - PubMed
  44. J Steroid Biochem Mol Biol. 2010 May 31;120(2-3):69-75 - PubMed

Publication Types